Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, insulin therapy and long-term monitoring, according to Vi ...
A moving journey through breast cancer, discovering that vulnerability is courage and a diagnosis doesn't have to define your spirit or faith. A breast cancer survivor shares how faith and community ...
Researchers at Moffitt Cancer Center are studying a new topical therapy called DYV800 that may help the immune system fight ...
New research shows that lymphoma survivors often face long-term peripheral neuropathy, which may be more severe than what ...
FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination. IMvigor011 randomized ...
Melanoma patients preparing for inpatient TIL therapy learn what to pack, how chemo feels, and how IL‑2 side effects are managed. Close monitoring during interleukin-2 (IL-2) therapy is essential for ...
A 15-patient, single-institution pilot longitudinally paired symptom surveys and stool profiling from baseline to 12 weeks after ICI initiation to explore microbiome–symptom associations. Fatigue ...
Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...
FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...
Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...
Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results